-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Infectious disease
-
Resource Type
- NICE Guidance
- Programme
- Year
- prev
- Page 12 of 2
11 results found filtered by Evidence Remove Evidence Filter Infectious disease Remove Infectious disease Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
NICE STA Guidance no 253 - Boceprevir for the treatment of genotype 1 chronic hepatitis C
- Published
- 25 April 2012
- Cycle of Improvement
- Evidence
-
NICE STA Guidance no 252 - Telaprevir for the treatment of genotype 1 chronic hepatitis C
- Published
- 25 April 2012
- Cycle of Improvement
- Evidence
-
No 200 – Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- Published
- 22 September 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 173 – Tenofovir disoproxil for the treatment of chronic hepatitis B
- Published
- 22 July 2009
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza
- Published
- 25 February 2009
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 153 - Entecavir for the treatment of chronic hepatitis B
- Published
- 27 August 2008
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 154 - Telbivudine for the treatment of chronic hepatitis B
- Published
- 27 August 2008
- Cycle of Improvement
- Evidence
-
Appraisal Guidance 106 Peginterferon alfa and ribavarin for mild chronic hepatitis C
- Published
- 27 September 2006
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 96 - Hepatitis B chronic - adefovir dipivoxil and peginterferon alfa-2a
- Published
- 22 February 2006
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 75 - interferon alfa and ribavirin for the treatment of chronic hepatitis C
- Published
- 21 January 2004
- Cycle of Improvement
- Evidence


